Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors

BRCA1 and BRCA2 both function in DNA double-strand break repair by homologous recombination (HR). Due to their HR-defect, BRCA1/2-deficient cancers are sensitive to poly(ADP-ribose) polymerase inhibitors (PARPi) but they eventually acquire resistance. Preclinical studies yielded several PARPi resist...

Full description

Bibliographic Details

Published in:	bioRxiv
Main Authors:	Bhin, Jinhyuk, Dias, Mariana Paes, Gogola, Ewa, Rolfs, Frank, Piersma, Sander R., de Bruijn, Roebi, de Ruiter, Julian R., van den Broek, Bram, Duarte, Alexandra A., Sol, Wendy, van der Heijden, Ingrid, Bakker, Lara, Kaiponen, Taina S., Lieftink, Cor, Morris, Ben, Beijersbergen, Roderick L., van de Ven, Marieke, Jimenez, Connie R., Wessels, Lodewyk F. A., Rottenberg, Sven, Jonkers, Jos
Format:	Paper
Language:	English
Published:	Cold Spring Harbor Laboratory 07.09.2022
Edition:	1.1
Subjects:	Cancer Biology homologous recombination PARP inhibitor multi-omics Breast cancer BRCA1 BRCA2 therapy resistance
ISSN:	2692-8205
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!